HealthQuill GSK Plc
GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract infections after the study achieved its goal on efficacy.
Drugs Health Pharma

GSK, Sepro end trial for oral drug to treat urinary tract infections

 HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.

Read More
The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.

Read More
GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2 billion in cash.
Drugs Health Pharma

GSK to buy Boston’s lead drug asset for liver disease for $2 billion in cash

HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple myeloma who have received at least one prior therapy.
Drugs Health Pharma

Britain gives green light for GSK Plc’s treatment of rare blood cancer

HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.

Read More
An oral antibiotic, gepotidacin, has shown efficacy in fighting gonorrhoea — one of the most prevalent sexually transmitted infections in the world, according to the results of an end-stage study published in The Lancet.
Drugs Health Research

Oral antibiotic shows efficacy in end-stage trials to treat gonorrhoea

HQ Team April 16, 2025: An oral antibiotic, gepotidacin, has shown efficacy in fighting gonorrhoea — one of the most prevalent sexually transmitted.

Read More
The US Food and Drug Administration has approved Britain’s GSK Plc’s drug to treat urinary tract infections in adult women and girls above 12 years, according to the company.
Drugs Medical Pharma

GSK’s drug to fight urinary tract infections gets USFDA approval

HQ Team March 26, 2025: The US Food and Drug Administration has approved Britain’s GSK Plc’s drug to treat urinary tract infections in.

Read More
GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Drugs Health Medical

GSK to pay Chimagen $300m upfront to develop autoimmune drug 

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

Read More
GSK Plc., will invest $800 million in its manufacturing facility in the US — the largest investment to date in the country — to make sterile liquid vaccines and medicines as demand grows.
Drugs Health Pharma

GSK to invest $800 million in US to double capacity at Marietta facility

GSK Plc., will invest $800 million in its manufacturing facility in the US — the largest investment to date in the country — to.

Read More
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season compared to 94.1% in the first and 64.2% in the second.
Drugs Health Pharma

GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year

GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.

Read More
The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.
Drugs Health Pharma

US regulator allows GSK’s endometrial cancer therapy for expanded use

The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.

Read More